FDA advisory panel backs Heplisav-B

29 July 2017

The US Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Friday voted 12 to 1 that the safety data for Heplisav-B (hepatitis B vaccine, recombinant [adjuvanted]) support licensure for immunization against hepatitis B infection in adults 18 years of age and older.

This would suggest that US immunotherapy specialist Dynavax Technologies’ (Nasdaq: DVAX) Heplisav-B could at last gain US marketing approval from the FDA, which has put obstacles in the way for the product’s registration since 2013, including a second Complete Response letter in November 2016.

Dynavax’ shares rocketed 80% to $16.55 in after-hours trading on Friday following the positive news coming out of the advisory panel meeting.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK